Researchers have developed a solid ‘cryogel’ vaccine that has been successful in combatting acute myeloid leukaemia in mice. How was this new formulation discovered and what potential does it have for cancer patients?
The AML vaccine is composed of a cryogel matrix that includes chemicals to attract and activate the body’s dendritic cells, which can initiate an immune response against the cancer cells and provide lasting immunity against recurrence of the disease (credit: Wyss Institute at Harvard University).
Chemotherapy has been the standard-of-care treatment for acute myeloid leukaemia (AML) for over 40 years. While it often causes the cancer to go into remission, it rarely completely eliminates the cancerous cells, leading to disease recurrence in nearly half of treated patients. Aggressive post-remission treatments, like high-dose chemotherapy or bone marrow transplants, can reduce the chance of recurrence, but many AML patients are not healthy enough to tolerate them.
A new study has presented an alternative treatment that has the potential to eliminate AML cells: an injectable, biomaterial-based vaccine that, when combined with standard chemotherapy, caused complete and lasting recovery from and immunity against the condition in mice.
…our AML vaccine… could finally provide long-term, relapse-free survival for AML patients”
Conducted by researchers from Harvard’s Wyss Institute for Biologically Inspired Engineering, John A. Paulson School of Engineering and Applied Sciences (SEAS) and Stem Cell Institute (SCI), all US, the study demonstrates the potential for a new AML vaccine formulation. The study was published in Nature Biomedical Engineering.
Are you looking to explore how lipid formulations in softgels can enhance drug absorption and bioavailability. Register for our upcoming webinar to find out!
3 September 2025 | 3:00 PM BST | FREE Webinar
This webinar will delve into the different types of lipid formulations, such as solutions, suspensions, emulsions, and self-(micro)emulsifying systems. Applications span diverse therapeutic areas including HIV therapy, oncology, immunosuppressants, and emerging treatments like medicinal cannabis (eg, CBD).
What You’ll Learn:
Lipid formulation development and screening tools for optimisation
Key steps in scale-up and industrialisation to ensure consistency and efficiency
Impact of lipid-based softgels on drug delivery and patient outcomes.
“We have previously developed cancer vaccines against solid tumours and we were curious to see if this technology would also be effective at treating a blood cancer like AML,” said co-first author Dr Nisarg Shah, a former Postdoctoral Fellow in the lab of Wyss Core Faculty member Dr David Mooney, who is now an Assistant Professor at the University of California, San Diego. “The promising outcomes of the combination of this vaccine with chemotherapy may translate to human vaccines that can be personalised yet offer off-the-shelf convenience.”
Developing a cryogel
Unlike traditional liquid vaccines, the new drug is a tiny, disk-shaped ‘cryogel’ scaffold made primarily of two materials – polyethylene glycol and alginate – that have been cross-linked together to form a matrix. Two chemicals (GM-CSF and CpG-ODN) are embedded in the scaffold to attract the body’s dendritic cells and activate them, along with antigens specific to AML cells (either contents from dead AML cells or a peptide from the protein WT-1). The activated dendritic cells take up the antigens from the vaccine site and present them to T cells, triggering them to seek and destroy AML cells as well as remain in the body to prevent any recurrence of disease.
To test whether their cryogel vaccine effectively primed the immune system to attack AML cells, the team injected it under the skin of healthy mice. They observed that it resulted in a much higher number of activated T cells when either AML cell contents or WT-1 was used as the antigen, compared with mice that received the activating chemicals via a traditional vaccine injection or a ‘blank’ scaffold without any chemicals. They then challenged the mice by injecting them with WT-1-expressing AML cells to mimic the initial onset of the disease. The mice that received either the traditional vaccine or a blank scaffold succumbed to the disease within 60 days, while those that received the cryogel vaccine survived. The survivors were then re-challenged with a second dose of AML cells after 100 days and displayed no signs of disease, demonstrating that the vaccine successfully protected them against recurrence.
As the disease originates in the bone marrow and cancerous cells can ‘hide’ there to escape chemotherapy treatment, the team analysed the mice’s bone marrow. They found large numbers of active T cells and no trace of AML cells in the cryogel-vaccinated mice’s marrow. When they transplanted bone marrow from those mice into healthy mice that were then challenged with AML cells, all the transplant recipients survived, while a control group succumbed to AML within 30 days, indicating that the immune protection against the condition was sustained and transferable.
Unexpected outcomes
To mimic the clinical scenario of a human patient developing AML, the team injected their cryogel vaccine into mice that had AML along with the standard chemotherapy regimen that AML patients receive, which causes AML cells to die in large numbers. The activated T-cell response in mice that received the combo therapy was six times higher than in mice that received chemotherapy plus a traditional liquid vaccine, suggesting that the cryogel was a much more effective vehicle for delivering the activating chemicals to the immune system.
To test the durability of the immune response generated by the combination treatment, they harvested bone marrow from mice that took the cryogel vaccine with WT-1 peptide along with chemotherapy. This was transplanted into healthy mice that were then challenged with the cancer. None of the recipient mice developed the disease up to 14 days after transplant, indicating that the combination-treated mice did not have residual AML cells in their marrow and all the recipient mice survived a later challenge with the cells, while untreated mice died within 31 days.
However, when the researchers began to investigate the vaccine’s components, they were surprised to find that that vaccines without an AML antigen were just as effective at providing protection as vaccines containing either AML cell contents or WT-1 peptide.
“We were definitely surprised and really did not expect this result, because we initially thought that including the antigen in the vaccine was critical. That led us down some research avenues we had not previously considered to try and understand what was going on,” said co-first author Alex Najibi, a graduate student in the Mooney lab. “We found that AML cells actually enter the cryogels over time, right where dendritic cells are already concentrated and activated. When the chemotherapy causes large numbers of AML cells to die, the dendritic cells can pick up their remains as antigens and generate a strong signal to activate T cells against AML.”
To further evaluate the efficacy of their antigen-free vaccine with chemotherapy, the team examined the bone marrow of mice with AML that received either the combination or the antigen-free vaccine alone. They found that the antigen-free vaccine alone did not effectively reduce the amount of AML cells in the marrow or increase the number of active T cells. However, the combined therapy achieved both of those goals. It also caused a decline in the number of regulatory T cells (Tregs) in the marrow, which suppress immune function and are thought to be a key reason why AML cells in the marrow evade immune detection.
Conclusion
The promising outcomes of the combination of this vaccine with chemotherapy may translate to human vaccines that can be personalised”
According to the researchers, work on the cryogel vaccine is continuing; the team is examining how it can be combined with sequencing technology to identify antigens that are specific to a single patient’s cancer and create a highly personalised vaccine. They are also exploring potential interactions with T cell and other adoptive transfer techniques, as well as researching antigen-free vaccines in the context of breast cancer.
“We are very excited about the performance of our AML vaccine, because it could finally provide long-term, relapse-free survival for AML patients, either to ‘clean up’ residual AML cells in the bone marrow following a stem cell transplant, or in older patients who cannot tolerate either transplants or high-dose chemotherapy,” said Mooney.
This website uses cookies to enable, optimise and analyse site operations, as well as to provide personalised content and allow you to connect to social media. By clicking "I agree" you consent to the use of cookies for non-essential functions and the related processing of personal data. You can adjust your cookie and associated data processing preferences at any time via our "Cookie Settings". Please view our Cookie Policy to learn more about the use of cookies on our website.
This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorised as ”Necessary” are stored on your browser as they are as essential for the working of basic functionalities of the website. For our other types of cookies “Advertising & Targeting”, “Analytics” and “Performance”, these help us analyse and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these different types of cookies. But opting out of some of these cookies may have an effect on your browsing experience. You can adjust the available sliders to ‘Enabled’ or ‘Disabled’, then click ‘Save and Accept’. View our Cookie Policy page.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Cookie
Description
cookielawinfo-checkbox-advertising-targeting
The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Advertising & Targeting".
cookielawinfo-checkbox-analytics
This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Analytics".
cookielawinfo-checkbox-necessary
This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-performance
This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Performance".
PHPSESSID
This cookie is native to PHP applications. The cookie is used to store and identify a users' unique session ID for the purpose of managing user session on the website. The cookie is a session cookies and is deleted when all the browser windows are closed.
viewed_cookie_policy
The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
zmember_logged
This session cookie is served by our membership/subscription system and controls whether you are able to see content which is only available to logged in users.
Performance cookies are includes cookies that deliver enhanced functionalities of the website, such as caching. These cookies do not store any personal information.
Cookie
Description
cf_ob_info
This cookie is set by Cloudflare content delivery network and, in conjunction with the cookie 'cf_use_ob', is used to determine whether it should continue serving “Always Online” until the cookie expires.
cf_use_ob
This cookie is set by Cloudflare content delivery network and is used to determine whether it should continue serving “Always Online” until the cookie expires.
free_subscription_only
This session cookie is served by our membership/subscription system and controls which types of content you are able to access.
ls_smartpush
This cookie is set by Litespeed Server and allows the server to store settings to help improve performance of the site.
one_signal_sdk_db
This cookie is set by OneSignal push notifications and is used for storing user preferences in connection with their notification permission status.
YSC
This cookie is set by Youtube and is used to track the views of embedded videos.
Analytics cookies collect information about your use of the content, and in combination with previously collected information, are used to measure, understand, and report on your usage of this website.
Cookie
Description
bcookie
This cookie is set by LinkedIn. The purpose of the cookie is to enable LinkedIn functionalities on the page.
GPS
This cookie is set by YouTube and registers a unique ID for tracking users based on their geographical location
lang
This cookie is set by LinkedIn and is used to store the language preferences of a user to serve up content in that stored language the next time user visit the website.
lidc
This cookie is set by LinkedIn and used for routing.
lissc
This cookie is set by LinkedIn share Buttons and ad tags.
vuid
We embed videos from our official Vimeo channel. When you press play, Vimeo will drop third party cookies to enable the video to play and to see how long a viewer has watched the video. This cookie does not track individuals.
wow.anonymousId
This cookie is set by Spotler and tracks an anonymous visitor ID.
wow.schedule
This cookie is set by Spotler and enables it to track the Load Balance Session Queue.
wow.session
This cookie is set by Spotler to track the Internet Information Services (IIS) session state.
wow.utmvalues
This cookie is set by Spotler and stores the UTM values for the session. UTM values are specific text strings that are appended to URLs that allow Communigator to track the URLs and the UTM values when they get clicked on.
_ga
This cookie is set by Google Analytics and is used to calculate visitor, session, campaign data and keep track of site usage for the site's analytics report. It stores information anonymously and assign a randomly generated number to identify unique visitors.
_gat
This cookies is set by Google Universal Analytics to throttle the request rate to limit the collection of data on high traffic sites.
_gid
This cookie is set by Google Analytics and is used to store information of how visitors use a website and helps in creating an analytics report of how the website is doing. The data collected including the number visitors, the source where they have come from, and the pages visited in an anonymous form.
Advertising and targeting cookies help us provide our visitors with relevant ads and marketing campaigns.
Cookie
Description
advanced_ads_browser_width
This cookie is set by Advanced Ads and measures the browser width.
advanced_ads_page_impressions
This cookie is set by Advanced Ads and measures the number of previous page impressions.
advanced_ads_pro_server_info
This cookie is set by Advanced Ads and sets geo-location, user role and user capabilities. It is used by cache busting in Advanced Ads Pro when the appropriate visitor conditions are used.
advanced_ads_pro_visitor_referrer
This cookie is set by Advanced Ads and sets the referrer URL.
bscookie
This cookie is a browser ID cookie set by LinkedIn share Buttons and ad tags.
IDE
This cookie is set by Google DoubleClick and stores information about how the user uses the website and any other advertisement before visiting the website. This is used to present users with ads that are relevant to them according to the user profile.
li_sugr
This cookie is set by LinkedIn and is used for tracking.
UserMatchHistory
This cookie is set by Linkedin and is used to track visitors on multiple websites, in order to present relevant advertisement based on the visitor's preferences.
VISITOR_INFO1_LIVE
This cookie is set by YouTube. Used to track the information of the embedded YouTube videos on a website.